vs
CytomX Therapeutics, Inc.（CTMX）与Finward Bancorp（FNWD）财务数据对比。点击上方公司名可切换其他公司
CytomX Therapeutics, Inc.的季度营收约是Finward Bancorp的1.1倍（$18.7M vs $16.5M），Finward Bancorp净利率更高（12.0% vs -0.8%，领先12.8%），Finward Bancorp同比增速更快（1.1% vs -25.7%），Finward Bancorp自由现金流更多（$9.0M vs $-15.8M），过去两年CytomX Therapeutics, Inc.的营收复合增速更高（-15.9% vs -19.1%）
CytomX Therapeutics是一家临床阶段生物技术公司，专注于创新癌症免疫疗法研发，依托专有的Probody技术平台开发仅在肿瘤微环境中激活的靶向疗法，可降低脱靶毒性，管线覆盖多种实体瘤适应症，还与全球头部药企合作推进相关治疗方案开发。
Finward Bancorp是一家总部位于美国的区域性银行控股公司，主要面向本土运营区域内的个人消费者与中小企业，提供储蓄账户、各类贷款、商业融资及财富管理等零售与商业金融服务。
CTMX vs FNWD — 直观对比
营收规模更大
CTMX
是对方的1.1倍
$16.5M
营收增速更快
FNWD
高出26.8%
-25.7%
净利率更高
FNWD
高出12.8%
-0.8%
自由现金流更多
FNWD
多$24.8M
$-15.8M
两年增速更快
CTMX
近两年复合增速
-19.1%
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.7M | $16.5M |
| 净利润 | $-154.0K | $2.0M |
| 毛利率 | — | — |
| 营业利润率 | -6.9% | 11.0% |
| 净利率 | -0.8% | 12.0% |
| 营收同比 | -25.7% | 1.1% |
| 净利润同比 | 97.6% | -5.6% |
| 每股收益（稀释后） | — | $0.46 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTMXFNWD
| Q4 25 | — | $16.5M | ||
| Q3 25 | — | $17.4M | ||
| Q2 25 | $18.7M | $16.6M | ||
| Q1 25 | $50.9M | $15.5M | ||
| Q4 24 | $38.1M | $16.3M | ||
| Q3 24 | $33.4M | $14.9M | ||
| Q2 24 | $25.1M | $14.6M | ||
| Q1 24 | $41.5M | $25.3M |
净利润CTMXFNWD
| Q4 25 | — | $2.0M | ||
| Q3 25 | — | $3.5M | ||
| Q2 25 | $-154.0K | $2.2M | ||
| Q1 25 | $23.5M | $455.0K | ||
| Q4 24 | $18.9M | $2.1M | ||
| Q3 24 | $5.7M | $606.0K | ||
| Q2 24 | $-6.5M | $143.0K | ||
| Q1 24 | $13.8M | $9.3M |
营业利润率CTMXFNWD
| Q4 25 | — | 11.0% | ||
| Q3 25 | — | 20.5% | ||
| Q2 25 | -6.9% | 12.7% | ||
| Q1 25 | 44.4% | 4.0% | ||
| Q4 24 | 46.4% | 16.3% | ||
| Q3 24 | 12.3% | 2.7% | ||
| Q2 24 | -33.7% | 0.9% | ||
| Q1 24 | 28.1% | 40.6% |
净利率CTMXFNWD
| Q4 25 | — | 12.0% | ||
| Q3 25 | — | 20.1% | ||
| Q2 25 | -0.8% | 12.9% | ||
| Q1 25 | 46.2% | 2.9% | ||
| Q4 24 | 49.6% | 12.9% | ||
| Q3 24 | 17.2% | 4.1% | ||
| Q2 24 | -26.0% | 1.0% | ||
| Q1 24 | 33.3% | 36.7% |
每股收益（稀释后）CTMXFNWD
| Q4 25 | — | $0.46 | ||
| Q3 25 | — | $0.81 | ||
| Q2 25 | — | $0.50 | ||
| Q1 25 | — | $0.11 | ||
| Q4 24 | — | $0.50 | ||
| Q3 24 | — | $0.14 | ||
| Q2 24 | — | $0.03 | ||
| Q1 24 | — | $2.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.0M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $119.9M | $174.7M |
| 总资产 | $175.1M | $2.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTMXFNWD
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $49.0M | — | ||
| Q1 25 | $47.6M | — | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $40.6M | — | ||
| Q2 24 | $43.2M | — | ||
| Q1 24 | $36.2M | — |
股东权益CTMXFNWD
| Q4 25 | — | $174.7M | ||
| Q3 25 | — | $165.5M | ||
| Q2 25 | $119.9M | $154.3M | ||
| Q1 25 | $25.0M | $151.8M | ||
| Q4 24 | $-456.0K | $151.4M | ||
| Q3 24 | $-23.5M | $159.6M | ||
| Q2 24 | $-31.2M | $148.6M | ||
| Q1 24 | $-31.7M | $151.6M |
总资产CTMXFNWD
| Q4 25 | — | $2.0B | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | $175.1M | $2.1B | ||
| Q1 25 | $98.5M | $2.0B | ||
| Q4 24 | $120.5M | $2.1B | ||
| Q3 24 | $139.0M | $2.1B | ||
| Q2 24 | $159.2M | $2.1B | ||
| Q1 24 | $184.7M | $2.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.8M | $9.9M |
| 自由现金流经营现金流 - 资本支出 | $-15.8M | $9.0M |
| 自由现金流率自由现金流/营收 | -84.6% | 54.8% |
| 资本支出强度资本支出/营收 | 0.1% | 5.2% |
| 现金转化率经营现金流/净利润 | — | 4.99× |
| 过去12个月自由现金流最近4个季度 | $-77.7M | $10.6M |
8季度趋势，按日历期对齐
经营现金流CTMXFNWD
| Q4 25 | — | $9.9M | ||
| Q3 25 | — | $1.2M | ||
| Q2 25 | $-15.8M | $4.8M | ||
| Q1 25 | $-21.0M | $-3.8M | ||
| Q4 24 | $-19.9M | $9.8M | ||
| Q3 24 | $-20.7M | $-3.7M | ||
| Q2 24 | $-19.5M | $2.8M | ||
| Q1 24 | $-26.0M | $-25.0K |
自由现金流CTMXFNWD
| Q4 25 | — | $9.0M | ||
| Q3 25 | — | $1.0M | ||
| Q2 25 | $-15.8M | $4.5M | ||
| Q1 25 | $-21.2M | $-4.0M | ||
| Q4 24 | $-20.0M | $6.7M | ||
| Q3 24 | $-20.7M | $-4.2M | ||
| Q2 24 | $-19.6M | $1.1M | ||
| Q1 24 | $-26.2M | $-736.0K |
自由现金流率CTMXFNWD
| Q4 25 | — | 54.8% | ||
| Q3 25 | — | 6.0% | ||
| Q2 25 | -84.6% | 27.0% | ||
| Q1 25 | -41.6% | -25.7% | ||
| Q4 24 | -52.5% | 41.2% | ||
| Q3 24 | -62.1% | -28.5% | ||
| Q2 24 | -78.2% | 7.6% | ||
| Q1 24 | -63.1% | -2.9% |
资本支出强度CTMXFNWD
| Q4 25 | — | 5.2% | ||
| Q3 25 | — | 0.9% | ||
| Q2 25 | 0.1% | 1.7% | ||
| Q1 25 | 0.2% | 1.2% | ||
| Q4 24 | 0.2% | 18.8% | ||
| Q3 24 | 0.1% | 3.4% | ||
| Q2 24 | 0.4% | 11.2% | ||
| Q1 24 | 0.3% | 2.8% |
现金转化率CTMXFNWD
| Q4 25 | — | 4.99× | ||
| Q3 25 | — | 0.34× | ||
| Q2 25 | — | 2.22× | ||
| Q1 25 | -0.89× | -8.37× | ||
| Q4 24 | -1.05× | 4.66× | ||
| Q3 24 | -3.61× | -6.15× | ||
| Q2 24 | — | 19.23× | ||
| Q1 24 | -1.89× | -0.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
FNWD
暂无分部数据
